Shots:

• The P-Ib/II CodeBreaK 101 study evaluates Lumakras + Vectibix in 31 patients with KRAS G12C-mutated advanced CRC
• The results demonstrated ORR (27%) among 26 patients in the efficacy analysis- DCR (81%)- 33% of patients experienced a response in the expansion cohort- no patients experienced dose-limiting toxicities during the 28 days following initial treatment. The therapy also demonstrated the efficacy and safety
• Amgen has completed an enrolment in P-III CodeBreaK 200 trial to evaluate sotorasib vs docetaxel in patients with KRAS G12C-mutated NSCLC. Lumakras is also being studied in multiple other solid tumors

  | Ref: PR Newswire | Image: Wall Street Journal